Targets › BCAT1
1 program from 1 company in 1 trial: 1 Phase 1; Oncology; next expected readout Sep 2027.
Catalyzes the first reaction in the catabolism of the essential branched chain amino acids leucine, isoleucine, and valine. (UniProt, P54687)
Open in Phaseline: the race on BCAT1, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Alnylam Pharmaceuticals | ALN-BCAT BCAT1 inhibitor | BCAT1 | Phase 1 | Advanced Hepatocellular Carcinoma | Sep 2027 |
Advanced Hepatocellular Carcinoma (1)
mixed (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.